Kornimate/medical-research-clean huggingface dataset:
endometrial cancer international database

Conditions: Endometrial Cancer

Summary: this project aims to determining prognostic factors and individualizing management decision per patient characteristics and endometrial cancer features. this study will include at least 10 centers from different countries that present at least europe, south america, asia, and africa. data will be retrospectively collected from january 2008 to december 2015 with a total follow-up of at least 5 years (december 2020).

endometrial cancer (ec) or carcinoma of corpus uteri is a neoplastic change, mostly adenocarcinoma, arising from uterine columnar epithelial lining. abnormal uterine bleeding is the main presenting symptom especially in postmenopausal women. ec is estimated to be the seventh most commonly diagnosed cancer in women. it is considered the 16th leading cause of death in women with cancer worldwide, with 382 000 estimated new cases and 89 900 deaths in 2018. factors as obesity, parity, diabetes mellitus, unopposed estrogen exposure, genetics and hormonal therapies are recognizable risks for ec. other factors as chronic comorbidities, tumor size and organ metastasis influence staging, prognosis, and management protocols. figo staging has been adopted as the standard classification system in the management of endometrial cancer. however, this staging system does not consider all factors that affect treatment decision and prognosis including but not limited to patient demographics, tumor grade, and lymphovascular space invasion. in addition, some interventions are still debatable particularly in the presence of intermediate disease e.g, grade ii early ec. available evidence supports combined pelvic and para-aortic lymphadenectomy in management of patients with ec. however, combined pelvic and para-aortic lymphadenectomy carry the risk of long term morbidities as lymphedema. thus, hysterectomy alone as management plan is suggested in patients with low risk ec. more comprehensive studies of the multiple confounders that determine patient's risk are essential to reach an individually adjusted management plans and to predict prognosis of each individual case. therefore, availability of large multicenter studies will provide robust evidence regarding optimal management of ec and hence, improve treatment outcome and prognosis particularly in the era of machine learning and artificial intelligence.

Eligibility criteria:
inclusion criteria: * women diagnosed with endometrial cancer, between 2008 and 2015. * women should be diagnosed and managed by the corresponding center. * patients with adequate clinical and pathological data. exclusion criteria: * inadequate information and follow-up for at least 5 years. * authorization to use anonymous patient data for research purposes.

Keywords: carcinoma of corpus uteri uterine malignancy figo staging adenocarcinoma lymphadenectomy hystrectomy prognosis prediction machine learning
the efficacy and safety of hlx208 in metastatic colorectal cancer (mcrc) with braf v600e mutation

Conditions: Metastatic Colorectal Cancer; mCRC

Summary: the purpose of this study was to assess efficacy, safety and pk in metastatic colorectal cancer (mcrc) given hlx208 (braf v600e inhibitor).


Eligibility criteria:
inclusion criteria: 1. age\>=18y; 2. good organ function; 3. expected survival time ≥ 3 months; 4. metastatic/recurrent advanced braf v600e mcrc that have been diagnosed histologically and have failed first line treatment; 5. at least one measurable lesion as per recist v1.1; 6. ecog score 0-1. exclusion criteria: 1. previous treatment with braf inhibitors or mek inhibitors 2. symptomatic brain or meningeal metastases (unless the patient has been on \> treatment for 6 months, has no evidence of progress on imaging within 4 weeks prior to initial administration, and tumor-related clinical symptoms are stable). 3. active clinical severe infection; 4. a history of other malignancies within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.
transfusion of red blood cells for acute respiratory distress syndrome(ards) in neonates

Conditions: Red Blood Cells(RBC); Acute Respiratory Distress Syndrome (ARDS)

Summary: acute respiratory distress syndrome (ards) in neonates has been defined in 2017. the death rate is over 50%.there are no special treatments for acute respiratory distress syndrome.

acute respiratory distress syndrome (ards) is one of the serious complications in critically ill neonates. it can result in severe hypoxemia refractory to mechanical ventilation. there are few options for mechanical ventilation for such situations such as high frequency oscillation ventilation and extracorporeal membrane oxygenation. the aim of the present study is to determine whether transfusion of red blood cells can decrease the mortality in neonate with ards.

Eligibility criteria:
inclusion criteria: * diagnosed with neonatal ards. * informed parental consent has been obtained exclusion criteria: * major congenital malformations or complex congenital heart disease * transferred out of the neonatal intensive care unit without treatment
superdimension™ navigation system version 7.2 with fluoroscopic navigation technology

Conditions: Lung Cancer

Summary: the purpose of this investigation is to confirm the clinical accuracy of the superdimension™ navigation system version 7.2 with fluoroscopic navigation technology.

the primary objective of this post-market feasibility study is to confirm the location accuracy of the local registration feature of the superdimension™ navigation system version 7.2 in subjects undergoing lung lesion biopsy.

Eligibility criteria:
inclusion criteria: 1. subject presents with lung lesion(s) 10 mm or greater in diameter amenable to evaluation by enb at the time of evaluation 2. lesion is intended to be biopsied by the participating investigator 3. subject is willing and able to provide informed consent to participate in the study 4. subject is a candidate for an elective enb procedure 5. subject is over the age of 18 exclusion criteria: 1. central lesions that are visible endobronchially or could be reached by a flexible bronchoscope or endobronchial ultrasound (ebus) without the utilization of enb 2. lesions within 10 mm of the diaphragm 3. the subject is unable or unwilling to comply with study follow-up schedule 4. the subject has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with this study 5. female subjects who are pregnant or nursing as determined by standard site practices
autologous mesenchymal stem cell transplantation in liver cirrhosis

Conditions: Liver Cirrhosis

Summary: this study is aiming to investigate the efficacy of autologous mesenchymal stem cell (msc) transplantation in 25 randomized patients with liver cirrhosis autologous mesenchymal stem cell will be derived from patients' bone marrows and will be infused via peripheral vein. liver biopsies will be performed in every patient in the beginning and at 6th month.


Eligibility criteria:
inclusion criteria: * radiological, clinical and histopathological diagnosis of liver cirrhosis * absence of hepatocellular carcinoma or any malignancies * no psychiatric disorder * no serous cardiovascular and pulmonary comorbidities * serum total bilirubin levels less than 5 mg/dl * platelet counts more than 30.000 mm3 * more than one year follow up period after initiation of antiviral drugs exclusion criteria: * alcohol intake in last one year * initiation of antiviral medication in last one year * systemic diseases

Keywords: liver cirrhosis autologous mesenchymal stem cell transplantation
a study about low blood pressure in patients with primary immunodeficiency disease treated with immune globulin products

Conditions: Primary Immune Deficiency Disorder

Summary: this is a safety study to evaluate the risk of low blood pressure in subjects with primary immune deficiency disorder (pid) treated with bivigam™ or another commercial product under real world conditions. no study medication will be provided to subjects in this study. study physicians will make all treatment decisions according to their usual practice and will provide prescriptions for his/her subjects, as appropriate. the only addition is the collection and structured documentation of data generated through usual practice.


Eligibility criteria:
inclusion criteria: * patients with pid diagnosis * current subjects requiring treatment with an igiv exclusion criteria: * patients not meeting inclusion criteria

Keywords: pid
a pilot study of therapist guided activity practice for depressive symptoms

Conditions: Depressive Symptoms

Summary: there is literature to support both the need for and efficacy of brief interventions for depressive symptoms, particularly among college students.brief behavioral activation interventions (batd) have gained recognition as efficacious treatments for depression; yet a recent study evidenced a substantial (39%) non-response rate (kuyken et al., 2017). in accordance with behavioral models of depression, the treatment involves increasing activity and positive experience, to break the negative reinforcement cycle maintaining depressed mood. thus, strategies that may facilitate increasing activity may improve batd outcomes. the objective of the current study is to examine whether briefly practicing a target activity during an activity planning session (modified single session of batd) increases the likelihood of completing the activity during the upcoming week. we hypothesized that guided activity practice may improve self-efficacy within session and activity completion in the upcoming week. we further aim to explore whether activity completion mediates depressive symptom change.


Eligibility criteria:
inclusion criteria: * ages 18-65 * university of texas at austin students currently enrolled in introductory psychology (psy 301) * score \>14 on beck depression inventory during both pre-screening and baseline screen * avoidance rating \>59 and distress rating \>39 on at least one item of the avoidance screen. exclusion criteria: * initiated psychotherapy or psychotropic medication in past 6 weeks * recent change (past 6 weeks) in psychotropic medication * current or past psychosis or mania
pain management after elective shoulder surgery

Conditions: Postoperative Pain

Summary: postoperative pain management plays an important role in elective shoulder surgery. the aim of this randomized quantitative study is to compare two frequently used postoperative pain regimes (hydromorphone versus piritramide) regarding onset and duration after the effectiveness of the single-shot interscalene block has diminished.


Eligibility criteria:
inclusion criteria: * all patients undergoing elective shoulder surgery with a single-shot interscalene plexus brachialis block in addition to general anesthesia * patients aged 18-99 years * patients being capable of giving an informed consent to participation in this study exclusion criteria: * patients aged below 18 years * patients with decompensated liver, heart or renal insufficiency * patients with any kind of lung disease * patients with a chronic pain syndrome * patients with a previous pain medication with more than 3 drugs over more than 3 months

Keywords: elective shoulder surgery, hydromorphone, piritramide
pilot study on metabolic effects of fish peptides and vitamin d

Conditions: Prediabetes; Insulin Resistance

Summary: the overall goal of this study is to investigate the effects and the mechanisms of action of a fish peptide and vitamin d on glucose metabolism, insulin secretion, and cardiometabolic risk profile in overweight men. transcriptomic and metabolomic approaches will be used to study the acute physiological effects of fish nutrients and to discover gene/metabolite networks that underlie these effects.

sedentary lifestyle and excess calorie intake have contributed to a dramatic increase in the occurrence of obesity, metabolic syndrome (mets), type 2 diabetes (t2d) and cardiovascular disease (cvd) the first step in reducing the excessive cvd risk associated with the presence of the mets is the adoption of a healthier lifestyle. a balanced diet, including high-nutritive and low-energy foods such as fish, is an important component of a healthy diet. fish is a major source of n-3 pufa, high-quality protein, and other essential nutrients such as vitamin d. fish consumption may therefore improve the components of the mets and reduce the incidence of t2d and cvd in obese subjects.the foundation of this project stems from the well-recognized fact that few canadians meet the weekly dietary recommendation for fish consumption (i.e. 2 servings/week) and thus intakes of both n-3 polyunsaturated fatty acid (pufa) and fish protein are low in the general population, and even lower in obese subjects. since some people simply dislike fish and because certain types of fish contain toxic contaminants, including heavy metals and environmental pollutants, fish consumption remains low. therefore, dietary choices limit intake of its key nutrients, thus increasing risk for mets, t2d and cvd. also, fish is one of the richest food sources of dietary vitamin d which may also contribute to the health benefits of fish consumption. indeed, it is currently estimated that ∼40% of canadians have low serum 25-hydroxyvitamin d \[25(oh)d\] concentrations (≤50 nm) and that ∼70% are below 75 nm. in addition, obesity is an important risk factor for low serum 25(oh)d.the main objective of this study is to investigate the acute effects and mechanisms of action of fish peptide and vitamin d on glucose metabolism, parameters of insulin sensibility and secretion, and cardiometabolic risk profile in overweight men. a four-arm randomized crossover design will be used to test the metabolic effects of consuming prior to a 3h-oral glucose tolerance test (ogtt), supplements containing either fish peptide (3 grams), vitamin d3 (1000 iu), a combination of fish peptide + vitamin d3 or a placebo.

Eligibility criteria:
inclusion criteria: * overweight (bmi 25-40 kg/m2) * fasting triglycerides ≥ 1.5 mmol/l * fasting insulin ≥ 60 pmol/l * non-smoking * stable weight in the past 3 months exclusion criteria: * diabetes * chronic diseases * taking drugs that could affect glucose or lipid metabolism * taking dietary supplements or natural health products * major surgery 3 months prior to the study * fish or seafood allergy * lactose intolerance
transplantation of autologous stem cells for the treatment of type 1 diabetes mellitus

Conditions: Diabetes Mellitus Type 1; Autoimmune Diseases; Endocrine System Diseases; Glucose Metabolism Disorders; Immune System Diseases; Metabolic Diseases

Summary: type 1 diabetes mellitus (t1dm) is a chronic, autoimmune condition that involves the progressive destruction of pancreatic β-cells, eventually resulting in the loss of insulin production and secretion. hence, an effective treatment for t1dm should focus on controlling anti-β-cell autoimmunity, combined with regeneration of lost pancreatic β-cell populations, with minimal risk to the patient. this is a phase i and ii clinical trial for treatment of patient with confirmed diagnosis of t1dm for at least 12 months prior to enrolment in this trial. this study aims to determine the combined effects of autologous stem cell transplantation and immunomodulation, on regeneration of lost β-cells and halting the immune attack on the pancreatic β-cells, respectively.

patients with t1dm depend on administration of exogenous insulin for survival and for control of long-term complications. the best-established treatment is constricted control of blood glucose accomplished by regular daily injections or constant subcutaneous infusion of insulin as intensive insulin therapy. although insulin therapy has advanced immensely, even the most modern technologies do not allow the maintenance of normal glucose levels. this is a prospective pilot study intended to treat patients with t1dm after at least one year of confirmed diagnosis. this study encompasses a two-arm approach; the first arm is composed of clinical-grade purification of autologous, leukapheresis-derived, cluster of differentiation 34+ and 133+ stem cells (accomplished by utilisation of clinimacs system and approved clinical-grade microbeads and accessories), and transplantation of the purified ell populations into pancreatic artery and capillaries via interventional radiology techniques; while the second arm aims at halting the immune attack on pancreatic β-cells through immunomodulation, and is composed of incubation of patient's leukapheresis with cord blood-derived mesenchymal stem cells for 3-6 hours, and return of the patient's own white blood cells back into the patient via intravenous injection. patients are first mobilised with 10 ug/kg granulocyte-colony stimulating factor (gcsf) for five day, and then mononuclear cells are collected from the patient via leukapheresis.

Eligibility criteria:
inclusion criteria: * confirmed type 1 diabetes mellitus diagnosed for at least 12 months prior to execution of this protocol. exclusion criteria: * pregnancy * severe psychiatric disorder * severe organic impairment (renal, hepatic, cardiac, pulmonary) * active infectious disease * previous or present neoplastic disease * any serious complications due to poor control of diabetes, including: lower limb ischemia, kidney failure, liver failure, vision impairment, peripheral neuropathies, poor circulation.

Keywords: stem cells transplantation immunomodulation cd34 cd133 clinicmacs
relationship between vitamin d and vitamin b12 levels and neuropathic pain in lipedema

Conditions: Vitamin D Deficiency; B12 Deficiency Vitamin; Lipedema

Summary: lipedema is a disease characterized by bilateral abnormal fat deposition in the upper and lower extremities. pain is a common symptom in lipedema.vitamin d plays an important role in chronic pain. vitamin b have analgesic role in some neuropathic pain conditions.this study aimedto evaluate the relationship between vitamin d and vitamin b12 levels and neuropathic pain in lipedema.

in this cross sectional study 200 lipedema patients will beincluded. according to paindetect questionnaire scores of cases with lipedema patients will be divided into two groups;an overall score of \> 13 likely or possible neuropathic pain (group 1) and \<13 unlikely np (group 2). patients' age, gender, comorbid diseases and laboratory values (25 oh vitamin d and vitamin b12 levels) will be recorded.

Eligibility criteria:
inclusion criteria: * the patients diagnosed byan experienced physical medicine and rehabilitation specialist for the diagnosis of lipedema exclusion criteria: * individuals who did not have 25(oh)d and b12 values in the past 6 months, * those with a history of gastrectomy or bypass surgery, * those consuming a vegetarian diet, those with lymphedema or chronic venous insufficiency, endocrine diseases, rheumatic diseases, malignancy, neurological diseases, and musculoskeletaldiseases that can be related to lower extremity neuropathic or nociceptivepain.

Keywords: vitamin d, b12 deficiency vitamin,lipedema,pain
a study of ro4995819 to assess bioavailability and safety in healthy volunteers

Conditions: Healthy Volunteer

Summary: this randomized, open-label, cross-over study will assess the bioavailability and safety of ro4995819 in healthy volunteers. volunteers will receive two different formulations (tablet and capsule) of the study drug under fed and fasting conditions.


Eligibility criteria:
inclusion criteria: * healthy non-smoking male and female volunteers, 18 to 65 years of age, inclusive. * a body mass index (bmi) between 18 to 30 kg/m2, inclusive. * able to participate and willing to give written informed consent and to comply with the study restrictions. * willing not to participate in any other clinical trial with an investigational drug or device for at least 3 months following the follow up visit. * male volunteers and their partners of childbearing potential must use two adequate methods of contraception. female volunteers who are not either surgically sterile or postmenopausal must commit to use two adequate methods of contraception throughout the study and until at least 5 months after last dosing. exclusion criteria: * history of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardio-vascular, endocrinological, hematological or allergic disease, metabolic disorder or cancer * significant past or present disorders of the central nervous system, psychiatric disorders, behavioral disturbances * diseases or medical conditions that are capable of altering the absorption, metabolism or elimination of drugs * any condition or disease detected during the medical interview / physical examination that would render the volunteer unsuitable for the study, place the volunteer at undue risk or interfere with the ability of the volunteer to complete the study in the opinion of the investigator * clinically significant abnormalities in laboratory test results * confirmed resting pulse rate greater than 90 or less than 40 beats per minute (bpm) at screening * confirmed systolic blood pressure (sbp) greater than 140 or less than 90 mm hg, and diastolic blood pressure (dbp) greater than 90 or less than 50 mm hg at screening * any major illness within the 4 weeks prior to dosing or any acute disease state within 7 days of study start * any confirmed allergic reaction against any drug or multiple allergies * any suspicion or history of alcohol abuse and/or consumption of other drugs of abuse * infection with hepatitis b, hepatitis c virus, or hiv 1 and hiv 2
undermining during cutaneous wound closure

Conditions: Wound Closure Techniques

Summary: the purpose of this study is to determine whether undermining during cutaneous surgery improves scar cosmesis compared to wound closure without undermining.

the purpose of this study is to determine whether undermining during cutaneous surgery improves scar cosmesis compared to wound closure without undermining. our aims are to compare outcomes using a split wound model, where half the wound is undermined and the other half is not. this will be measured via the physician observer scar assessment scale, a validated scar instrument and via wound width. our hypothesis is that wound undermining will result in cosmetically superior wound outcomes.

Eligibility criteria:
inclusion criteria: * able to give informed consent themselves * patient scheduled for cutaneous surgical procedure with predicted linear closure * willing to return for follow up visits exclusion criteria: * mentally handicapped * incarceration * pregnant women * wounds with predicted closure length less than 3 cm * wounds with diameter \> 3 cm * wounds unable to be fully closed without undermining